MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

PURPOSE: The phase 2 MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor positive (HR+), HER2− metastatic breast cancer (MBC). EXPERIMENTAL DESIGN: MONARCH...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581697/
https://ncbi.nlm.nih.gov/pubmed/28533223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0754
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы